RPL26P26

Across TCGA pan-cancer cohorts, RPL26P26 RNA differs between tumor and matched normal tissue in 3 of 18 cancer types tested, making tumor–normal expression one of RPL26P26’s most consistent transcriptional readouts.

The strongest signal is observed in breast invasive carcinoma (BRCA), where RPL26P26 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types RPL26P26 is over-expressed in tumor, although a few such as KIRC show the opposite, repressed pattern.

BRCA, COAD, and KIRC are the cancer types where RPL26P26 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in RPL26P26 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
BRCA	Female	II,III,IV	+0.191	.015	4	view →
COAD	All	All	+0.064	.030	1	view →
KIRC	All	IV	−0.026	.037	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 3 strongest of 3 lineages.

RPL26P26–BRCA

Open the BRCA breakdown →